These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 34125226)

  • 1. Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study.
    Kuijpers SME; Wiepjes CM; Conemans EB; Fisher AD; T'Sjoen G; den Heijer M
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e3936-e3945. PubMed ID: 34125226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of gender affirming hormone treatment in transgender individuals - a retrospective cohort study.
    Muir CA; Guttman-Jones M; Man EJ
    Endocrine; 2024 Jul; 85(1):370-379. PubMed ID: 38386168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.
    Wierckx K; Van Caenegem E; Schreiner T; Haraldsen I; Fisher AD; Toye K; Kaufman JM; T'Sjoen G
    J Sex Med; 2014 Aug; 11(8):1999-2011. PubMed ID: 24828032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women.
    Fung R; Hellstern-Layefsky M; Tastenhoye C; Lega I; Steele L
    J Sex Med; 2016 Nov; 13(11):1765-1772. PubMed ID: 27693265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transient Elevated Serum Prolactin in Trans Women Is Caused by Cyproterone Acetate Treatment.
    Defreyne J; Nota N; Pereira C; Schreiner T; Fisher AD; den Heijer M; T'Sjoen G
    LGBT Health; 2017 Oct; 4(5):328-336. PubMed ID: 28880825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of 5-year administration of cyproterone acetate or leuprolide acetate in combination with estradiol in transwomen.
    Gava G; Mancini I; Alvisi S; Seracchioli R; Meriggiola MC
    Eur J Endocrinol; 2020 Dec; 183(6):561-569. PubMed ID: 33055297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiometabolic Effects of Testosterone in Transmen and Estrogen Plus Cyproterone Acetate in Transwomen.
    van Velzen DM; Paldino A; Klaver M; Nota NM; Defreyne J; Hovingh GK; Thijs A; Simsek S; T'Sjoen G; den Heijer M
    J Clin Endocrinol Metab; 2019 Jun; 104(6):1937-1947. PubMed ID: 30602016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-Dose Cyproterone Acetate Treatment for Transgender Women.
    Even Zohar N; Sofer Y; Yaish I; Serebro M; Tordjman K; Greenman Y
    J Sex Med; 2021 Jul; 18(7):1292-1298. PubMed ID: 34176757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low estrogen doses normalize testosterone and estradiol levels to the female range in transgender women.
    Cunha FS; Domenice S; Sircili MHP; Mendonca BB; Costa EMF
    Clinics (Sao Paulo); 2018; 73():e86. PubMed ID: 29723345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years.
    Madsen MC; van Dijk D; Wiepjes CM; Conemans EB; Thijs A; den Heijer M
    J Clin Endocrinol Metab; 2021 May; 106(6):1710-1717. PubMed ID: 33599731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gender-affirming hormone treatment modalities for transfemale & non-binary transfeminine individuals: A UK perspective.
    Sagar RC; Millson-Brown V
    Best Pract Res Clin Endocrinol Metab; 2024 Sep; 38(5):101921. PubMed ID: 39232976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents.
    Tack LJW; Heyse R; Craen M; Dhondt K; Bossche HV; Laridaen J; Cools M
    J Sex Med; 2017 May; 14(5):747-757. PubMed ID: 28499525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Androgenic Effects Comparison Between Cyproterone Acetate and Spironolactone in Transgender Women: A Randomized Controlled Trial.
    Burinkul S; Panyakhamlerd K; Suwan A; Tuntiviriyapun P; Wainipitapong S
    J Sex Med; 2021 Jul; 18(7):1299-1307. PubMed ID: 34274044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and rapid efficacy of guideline-based gender-affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria.
    Meyer G; Mayer M; Mondorf A; Flügel AK; Herrmann E; Bojunga J
    Eur J Endocrinol; 2020 Feb; 182(2):149-156. PubMed ID: 31751300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serum hormones before and during therapy with cyproterone acetate and spironolactone in patients with androgenization].
    Grunwald K; Rabe T; Schlereth G; Runnebaum B
    Geburtshilfe Frauenheilkd; 1994 Nov; 54(11):634-45. PubMed ID: 8719011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactinoma induced by estrogen and cyproterone acetate in a male-to-female transsexual.
    García-Malpartida K; Martín-Gorgojo A; Rocha M; Gómez-Balaguer M; Hernández-Mijares A
    Fertil Steril; 2010 Aug; 94(3):1097.e13-5. PubMed ID: 20227072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate Cancer Incidence under Androgen Deprivation: Nationwide Cohort Study in Trans Women Receiving Hormone Treatment.
    de Nie I; de Blok CJM; van der Sluis TM; Barbé E; Pigot GLS; Wiepjes CM; Nota NM; van Mello NM; Valkenburg NE; Huirne J; Gooren LJG; van Moorselaar RJA; Dreijerink KMA; den Heijer M
    J Clin Endocrinol Metab; 2020 Sep; 105(9):e3293-9. PubMed ID: 32594155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Estrone in Feminizing Hormone Treatment.
    Tebbens M; Heijboer AC; T'Sjoen G; Bisschop PH; den Heijer M
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e458-e466. PubMed ID: 34632510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testosterone and other treatments for transgender males and non-binary trans masculine individuals.
    Dimakopoulou A; Seal LJ
    Best Pract Res Clin Endocrinol Metab; 2024 Sep; 38(5):101908. PubMed ID: 38997938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
    Meriggiola MC; Bremner WJ; Costantino A; Di Cintio G; Flamigni C
    Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.